Product Name:
JAK3-3
Product Number:
ab-nk086-2
Target Full Name: Janus protein-tyrosine kinase 3
Target Alias: JAK-3; JAK3_HUMAN; JAKL; Janus kinase 3; Kinase JAK3; Leukocyte janus kinase; LJAK; L-JAK; CCDS12366.1; ENSG00000105639
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK086-4
Antibody Target Type: Pan-specific
Protein UniProt: P52333
Protein SigNET: P52333
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human JAK3 sequence peptide Cat. No.: PE-01AUR99
Antibody Immunogen Sequence: CFTAHPEGKHHSLSFS
Antibody Immunogen Description: Corresponds to amino acid residues F1110 to S1124; C-terminus
Production Method: Corresponds to amino acid residues F1110 to S1124; C-terminus
Antibody Modification: Protein kinase pan-specific antibody
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Strong immunoreactivity with recombinant human JAK3 on protein dot blots.
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 110-125 kDa.
Antibody Specificity: High
Antibody Cross Reactivity: Very weak immunoreactivity on protein dot blots with recombinant human JAK1 and JAK2, and no immunoreactivity with Tyk2.
Related Product 1: JAK3-3 blocking peptide
Related Product 2: JAK3-1 pan-specific antibody (Cat. No.: AB-NK086-2)
Related Product 3: JAK3-2 pan-specific antibody (Cat. No.: AB-NK086-3)
Related Product 4: JAK3-pY980+pY981 phosphosite-specific antibody (Cat. No.: AB-PK669)
Related Product 5: JAK3Selectide - JAK3 protein kinase substrate peptide
Scientific Background: JAK3 is a protein-tyrosine kinase of the TK group and JAKA family. Phosphorylation at T8, Y904 and Y980 increases phosphotransferase activity. Phosphorylation at Y939 also increases phosphotransferase activity and induces interaction with STAT5A. Phosphorylation at Y785 induces interaction with SH2-B-beta. Phosphorylation at Y981 inhibits phosphotransferase activity. It is involved in cytokine receptor-mediated intracellular signal transduction, including activation of an oncoprotein, PI3K. JAK3 may be an oncoprotein (OP). JAK3 mutations were commonly found in juvenile myelomonocytic leukemia from whole-exome sequencing studies from 13 individuals. JAK3 were hypothesized to be involved in the progression rather than the initiation of leukemia, and patients with mutated JAK3 were associated with poorer clinical results. Mutations in this gene have been found in blood, mouth, and ovarian cancers.
